Literature DB >> 11706420

EGFR and PCNA expression in oral squamous cell carcinomas--a valuable tool in estimating the patient's prognosis.

S Störkel1, T Reichert, K A Reiffen, W Wagner.   

Abstract

We investigated 100 cases of oral squamous cell carcinomas immunohistologically with respect to the expression of the epidermal growth factor receptor (EGFR) and the proliferating cell nuclear antigen (PCNA). The results were correlated with a new malignancy grading of the invasive tumour areas and the clinical outcome of the patients to estimate the individual prognosis. In conclusion, the amount of antigen expression of both antigens increases with the increasing grade of malignancy of the oral squamous cell carcinoma. Furthermore, there is a statistically significant correlation between the amount of antigen expression and the patient's prognosis. An overexpression of EGFR and PCNA is associated with a short survival of the patient. Both antigens detect relevant tumour biological parameters and are worthy factors in estimating the individual prognosis in patients suffering from oral squamous cell carcinomas.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 11706420     DOI: 10.1016/0964-1955(93)90047-i

Source DB:  PubMed          Journal:  Eur J Cancer B Oral Oncol        ISSN: 0964-1955


  11 in total

1.  Immunohistochemical expression of EGFR and p-EGFR in oral squamous cell carcinomas.

Authors:  Yukihiro Hiraishi; Takeshi Wada; Ken Nakatani; Kenji Negoro; Shigeyuki Fujita
Journal:  Pathol Oncol Res       Date:  2006-06-24       Impact factor: 3.201

2.  Gene expression profiling of oral squamous cell carcinoma by differential display rt-PCR and identification of tumor biomarkers.

Authors:  Sanjukta Chakraborty; M N Nagashri; S M Azeem Mohiyuddin; K S Gopinath; Arun Kumar
Journal:  Indian J Surg Oncol       Date:  2011-02-18

Review 3.  Targeting epidermal growth factor receptor and SRC pathways in head and neck cancer.

Authors:  Ann Marie Egloff; Jennifer R Grandis
Journal:  Semin Oncol       Date:  2008-06       Impact factor: 4.929

4.  Proliferating Cell Nuclear Antigen in Premalignancy and Oral Squamous Cell Carcinoma.

Authors:  Chandrashekar Poosarla; Maya Ramesh; K Ramesh; Swetha Gudiseva; Sekar Bala; Murali Sundar
Journal:  J Clin Diagn Res       Date:  2015-06-01

5.  A multifactorial approach including tumoural epidermal growth factor receptor, p53, thymidylate synthase and dihydropyrimidine dehydrogenase to predict treatment outcome in head and neck cancer patients receiving 5-fluorouracil.

Authors:  M C Etienne; X Pivot; J L Formento; R J Bensadoun; P Formento; O Dassonville; M Francoual; G Poissonnet; X Fontana; M Schneider; F Demard; G Milano
Journal:  Br J Cancer       Date:  1999-04       Impact factor: 7.640

Review 6.  Circulating tumor cells in head and neck cancer: A review.

Authors:  Kyle P McMullen; Jeffrey J Chalmers; Jas C Lang; Pawan Kumar; Kris R Jatana
Journal:  World J Otorhinolaryngol Head Neck Surg       Date:  2016-07-21

7.  Changes in cell junctions induced by inhibition of epidermal growth factor receptor in oral squamous cell carcinoma cells.

Authors:  Yasumasa Kakei; Shun Teraoka; Masaya Akashi; Takumi Hasegawa; Takahide Komori
Journal:  Exp Ther Med       Date:  2017-06-14       Impact factor: 2.447

8.  Expression of epidermal growth factor receptor in oral and esophageal squamous-cell carcinoma.

Authors:  Fatemeh Shahsavari; Rosa Miri; Maedeh Ghorbanpour
Journal:  Dent Res J (Isfahan)       Date:  2020-03-17

9.  Lack of relationship between EGFR-1 immunohistochemical expression and prognosis in a multicentre clinical trial of 93 patients with advanced primary ovarian epithelial cancer (GINECO group).

Authors:  C Elie; J F Geay; M Morcos; A Le Tourneau; V Girre; P Broët; B Marmey; L Chauvenet; J Audouin; E Pujade-Lauraine; S Camilleri-Broët
Journal:  Br J Cancer       Date:  2004-08-02       Impact factor: 7.640

10.  Prognostic significance of EGFR and Her-2 in oral cavity cancer in betel quid prevalent area cancer prognosis.

Authors:  I-H Chen; J T Chang; C-T Liao; H-M Wang; L-L Hsieh; A-J Cheng
Journal:  Br J Cancer       Date:  2003-08-18       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.